Key result
Natural bioproducts show promise as cardiovascular epidrugs by targeting key epigenetic mechanisms.
Answers are grounded in this paper and cite their sources.
Naturally derived bioproducts with epigenetic properties offer promising therapeutic prospects for the prevention and management of cardiovascular disorders.
Cardiovascular disorders (CVDs) are the leading cause of mortality worldwide, highlighting an urgent need for innovative therapeutic strategies. Recent advancements highlight the potential of naturally derived bioproducts with epigenetic properties to offer protection against CVDs. These compounds act on key epigenetic mechanisms, DNA methylation, histone modifications, and non-coding RNA regulation to modulate gene expression essential for cardiovascular health. This review explores the effects of various bioproducts, such as polyphenols, flavonoids, and other natural extracts, on these epigenetic modifications and their potential benefits in preventing and managing CVDs. We discuss recent discoveries and clinical applications, providing insights into the epigenetic regulatory mechanisms of these compounds as potential epidrugs, naturally derived agents with promising therapeutic prospects in epigenetic therapy for CVDs.
No takes yet. Share an insight, caveat, or question.
Martínez-Iglesias et al. (2025) conducted a review in Cardiovascular disorders. Naturally derived bioproducts (polyphenols, flavonoids) was evaluated. Naturally derived bioproducts, such as polyphenols and flavonoids, modulate key epigenetic mechanisms and offer promising therapeutic prospects as epidrugs for cardiovascular disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: